Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables: 2022-2024

Historic Receivables for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $155.5 million.

  • Axsome Therapeutics' Receivables rose 55.97% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $766.2 million, marking a year-over-year increase of 54.98%. This contributed to the annual value of $155.5 million for FY2024, which is 44.90% up from last year.
  • Per Axsome Therapeutics' latest filing, its Receivables stood at $155.5 million for FY2024, which was up 44.90% from $107.3 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Receivables registered a high of $155.5 million during FY2024, and its lowest value of $46.8 million during FY2022.
  • For the 3-year period, Axsome Therapeutics' Receivables averaged around $103.2 million, with its median value being $107.3 million (2023).
  • Data for Axsome Therapeutics' Receivables shows a peak YoY spiked of 129.34% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Receivables (Yearly) stood at $46.8 million in 2022, then spiked by 129.34% to $107.3 million in 2023, then spiked by 44.90% to $155.5 million in 2024.